Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A
Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A
The purpose of this study is to determine the immunologic and overall safety associated with
 long-term use of Alphanate in subjects diagnosed with severe hemophilia A (Factor VIII:C less
 than 0.01 IU/ml), who have been previously treated with plasma-derived Factor VIII products
 other than Alphanate and who have no history of developing either antibody inhibitors to
 Factor VIII or nonspecific inhibitors of coagulation.
This is a Phase IV, non-randomized, multicenter study of at least 50 evaluable subjects
 diagnosed with severe hemophilia A. Enrolled subjects will be treated at home and with
 in-clinic therapy exclusively with Alphanate as their sole source of Factor VIII concentrate
 for prophylaxis and treatment of all bleeding episodes and surgical procedures. Subjects will
 be treated for at least 2 years and a minimum of 50 exposure days, or if 50 exposure days are
 not reached, for a maximum of 30 months and in accordance with the subject's usual pre-study
 treatment regimen. Subjects will continue treatment as above or until they develop inhibitors
 to Factor VIII at a titer greater than or equal to 5 Bethesda units (BU/ml); Factor VIII
 becomes ineffective at providing hemostasis, or the subject exhibits severe or serious
 adverse events that prevent completion of the study.
Inclusion Criteria:

 -  Male

 -  At least 6 years of age and not more than 65 years of age.

 -  Signed and dated Informed Consent Form and Patient Authorization for Release of
 Information approved by the appropriate Institutional Review Board (IRB) prior to
 screening and enrollment. If the subject is a minor (i.e., less than 18 years of age)
 both he and his parent or legal guardian must sign and date the informed consent.

 -  Diagnosis of severe hemophilia A

 -  Levels of Factor VIII less than 0.01 IU/mL.

 -  Treatment with cryoprecipitate, Factor VIII concentrates, and/or whole blood, for at
 least 150 cumulative exposure days (CEDs) prior to enrollment.

 -  No treatment with cryoprecipitate, Factor VIII concentrate, or any other blood
 product, for at least 72 hours prior to screening.

 -  No previous diagnosis with inhibitors to Factor VIII at any detectable titer.

 -  Subjects must never have been diagnosed with nonspecific inhibitors of coagulation.

 -  Negative test for the presence of Factor VIII inhibitors at screening and enrollment.

 -  CD4 counts greater than or equal to 400 cells/µL.

 -  Vaccination against hepatitis A and hepatitis B, or evidence of antibodies against
 hepatitis A and hepatitis B. (A subject who has no prior immunity against hepatitis A
 will be offered a course of vaccination for hepatitis A.)

 -  Karnofsky Performance Score of at least 50.

 Exclusion Criteria:

 -  Any immunosuppressive medications including intravenous immunoglobulins at the time of
 enrollment.

 -  Clinical signs or symptoms of an infection, such as fever, chills or nausea during
 screening or enrollment.

 -  History of frequent reactions to Factor VIII concentrates (e.g., chills or headaches).

 -  Prior treatment with Alphanate® (Solvent-Detergent/ Heat-Treated).

 -  Immunocompromised (including HIV+ status or has an impaired immune system due to
 disease or treatment).